Physician Photo

Steven Kyle Grinspoon, MD

Clinical Director, Neuroendocrine Clinical Center

Director, MGH Program in Nutritional Metabolism

  • Phone: 617-726-3890
Department of Medicine
Clinical Interests
Pituitary disease
Endocrine manifestations of AIDS
Boston: Massachusetts General Hospital
Medical Education
MD, University of Rochester School of Medicine and Dentistry
Residency, New York Presbyterian Hospital
Fellowship, Massachusetts General Hospital
Board Certifications
Endocrinology, Diabetes & Metabolism, American Board of Internal Medicine
Patient Age Group
Accepting New Patients


I am the Clinical Director of the Neuroendocrine Clinical Center at the MGH and also head a multidisplinary research program, the MGH Program in Nutritional Metabolism, focusing on obesity, regulation of substrate metabolism, body composition and neuroendocrine signaling of appetite and energy balance.


Dr. Grinspoon and members of his research group have made major contributions to the understanding of reduced GH secretion in visceral obesity, the relationship of excess visceral fat to cardiovascular risk, and to the development of novel neuroendocrine strategies to reduce this risk among patients with fat redistribution syndromes, including lipodystrophy and generalized obesity.  Addressing the issue of visceral fat accumulation and it's reltionship to cardiovascular risk, Dr. Grinspoon has performed studies to show that pulsatile GH secretion is reduced in tight association with excess visceral obesity, and has led the development of a potentially new drug strategy using growth hormone releasing hormone (GHRH) to increase endogenous pulsatile GH, and selectively reduce visceral fat among lipodystrophic patients. He has studied the consequences of subclinical inflammation among patients with generalized and obesity and developed novel strategies to reduce insulin resisitance by blocking TNF-alpha.  

Diabetes drug halts atherosclerosis progression in HIV-infected patients

Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV.

Increased cardiovascular risk in HIV-infected patients may relate to arterial inflammation

The elevated risk of cardiovascular disease seen in patients infected with HIV appears to be associated with increased inflammation within the arteries, according to a study in a special issue of JAMA published in conjunction with the International AIDS Conference.

Differences in plaque composition, immune activation may explain elevated cardiovascular risk in HIV-infected women

An MGH research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men.

Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.

Program in Nutritional Metabolism
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-3890
Phone 2: 617-724-9109
Fax: 617-724-8998

Neuroendocrine Clinical Center
Zero Emerson Place
Boston, MA 02114-2217

Phone: 617-726-7948
Phone 2: 617-726-6813
Fax: 617-726-1241